As of Nov 19, 2026, 1 of 1 active firms rate INMB a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
INMB EPS & revenue forecast
EPS · NEXT QUARTER
$-0.18
Range $-0.18 – $-0.18 · 1 analysts · -10% YoY
Next period, 1 analysts expect INmune Bio Inc to earn $-0.18 a share (range $-0.18 – $-0.18), versus $-0.20 a year earlier. Full-year consensus is $-0.58, growing to $-0.43 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 1 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $15.2M next year.
Top analysts covering INmune Bio Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on INMB.
#1
George Farmer
Scotiabank · Rank #311
Sell
$0.60-40.9% to target
Overall win rate
44%
+ Follow
#2
Thomas Shrader
BTIG · Rank #553
Neutral
No targeton INMB
Overall win rate
32%
+ Follow
#3
Jason McCarthy
Maxim Group · Rank #567
Buy
$8.00+688.2% to target
Overall win rate
30%
+ Follow
#4
James Molloy
Alliance Global Partners · Rank #587
Buy
$7.00+589.7% to target
Overall win rate
25%
+ Follow
#5
Elemer Piros
Lucid Capital
Buy
$9.00+786.7% to target
Coverage
—
+ Follow
INMB stock forecast FAQ
What is INMB's average 12-month price target?+
The 1 active firms with a live target average $9.00 for INmune Bio Inc over the next 12 months, ranging from a $9.00 high to a $9.00 low, as of Nov 19, 2026.
Is INMB stock a Buy, Sell or Neutral right now?+
The current consensus is Insufficient coverage. Of the 1 active firms as of Nov 19, 2026, 1 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
How many active Wall Street firms cover INMB?+
1 active firms have a recognized rating on INmune Bio Inc as of Nov 19, 2026, and 1 active firms carry a live 12-month price target.
Who is the most accurate analyst covering INMB?+
Among analysts who currently cover INMB, George Farmer of Scotiabank has the strongest overall Quantellect track record (Rank #311). Their current call is Sell with a $0.60 target.
What is INmune Bio Inc's projected EPS for next quarter?+
The consensus estimate is $-0.18 per share (range $-0.18 – $-0.18) across 1 analysts. Full-year EPS is projected at $-0.58, rising to $-0.43 the following year.
How much revenue is INmune Bio Inc expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $15.2M next year.
Have analysts been upgrading or downgrading INMB lately?+
As of Nov 19, 2026, 1 of 1 active firms rate INMB a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their INMB calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.